HomeCompareEMPYF vs ABBV

EMPYF vs ABBV: Dividend Comparison 2026

EMPYF yields 293.04% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EMPYF wins by $1293.51M in total portfolio value
10 years
EMPYF
EMPYF
● Live price
293.04%
Share price
$0.68
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1293.61M
Annual income
$774,021,181.48
Full EMPYF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — EMPYF vs ABBV

📍 EMPYF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEMPYFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EMPYF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EMPYF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EMPYF
Annual income on $10K today (after 15% tax)
$24,908.42/yr
After 10yr DRIP, annual income (after tax)
$657,918,004.26/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, EMPYF beats the other by $657,896,948.25/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EMPYF + ABBV for your $10,000?

EMPYF: 50%ABBV: 50%
100% ABBV50/50100% EMPYF
Portfolio after 10yr
$646.86M
Annual income
$387,022,976.62/yr
Blended yield
59.83%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

EMPYF
No analyst data
Altman Z
8.7
Piotroski
7/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EMPYF buys
0
ABBV buys
0
No recent congressional trades found for EMPYF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEMPYFABBV
Forward yield293.04%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$1293.61M$102.3K
Annual income after 10y$774,021,181.48$24,771.77
Total dividends collected$1241.10M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: EMPYF vs ABBV ($10,000, DRIP)

YearEMPYF PortfolioEMPYF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$40,004$29,304.03$11,550$430.00+$28.5KEMPYF
2$152,363$109,558.81$13,472$627.96+$138.9KEMPYF
3$553,006$389,977.58$15,906$926.08+$537.1KEMPYF
4$1,914,552$1,322,835.81$19,071$1,382.55+$1.90MEMPYF
5$6,328,726$4,280,154.80$23,302$2,095.81+$6.31MEMPYF
6$19,994,576$13,222,839.70$29,150$3,237.93+$19.97MEMPYF
7$60,436,630$39,042,433.57$37,536$5,121.41+$60.40MEMPYF
8$174,958,464$110,291,269.98$50,079$8,338.38+$174.91MEMPYF
9$485,600,924$298,395,367.51$69,753$14,065.80+$485.53MEMPYF
10$1,293,614,171$774,021,181.48$102,337$24,771.77+$1293.51MEMPYF

EMPYF vs ABBV: Complete Analysis 2026

EMPYFStock

Empress Royalty Corp. acquires royalty and streaming interests in precious metal mines and mining projects. The company has a portfolio of 17 precious metals royalties in Canada. It has net smelter return royalty interests in the Pinos Royalty and McLeroy-Pinos Royalty in the Pinos gold-silver project in Mexico. The company was incorporated in 2020 and is headquartered in White Rock, Canada.

Full EMPYF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this EMPYF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EMPYF vs SCHDEMPYF vs JEPIEMPYF vs OEMPYF vs KOEMPYF vs MAINEMPYF vs JNJEMPYF vs MRKEMPYF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.